
BOTOX® Cosmetic Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"
The approvals are supported by results of the pivotal Phase 3 SELECT-GCA clinical trial, which met the primary endpoint of sustained remission* (46.4% of patients receiving RINVOQ 15 mg in combination with a 26-week steroid taper regimen achieved sustained …